Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billi...( Percentage of Biologic-Treated Psoria...),Health

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the next decade.

The new Pharmacor report entitled Psoriasis finds that the overall psoriasis drug market will grow from $2.3 billion in 2007 to $5 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Following their launches by 2012, the uptake of Stelara and Abbott's ABT-874 will be particularly robust, owing to their novel mechanism of action, durable efficacy and infrequent administration. In 2017, Stelara and ABT-874 will capture 21 percent of sales in the moderate to severe psoriasis market.

Between 2007 and 2017, up to nine biologics will be available to treat psoriasis and the number of biologic-treated patients in the psoriasis market will grow significantly, according to the report. Among patients treated with a systemic drug therapy, the percentage of biologic-treated patients will double, growing from 23 percent in 2007 to 46 percent in 2017.

"With the recent launch of Humira and the highly anticipated launch of Stelara as early as December 2008, we expect a reshuffling to occur in the current order of first-line biologic agents for the treatment of psoriasis," said Joanna Kim, analyst at Decision Resources. "We forecast that Humira and Stelara will join Enbrel as first-line biologics for moderate to severe psoriasis by 2012."

About Decision Resources

Decision Resources (